CA3077910A1 — Modulation of alpha synuclein expression
Assigned to Ionis Pharmaceuticals Inc · Expires 2012-05-24 · 14y expired
What this patent protects
Disclosed herein are antisense compounds and methods for decreasing alpha- synuclein mRNA and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.
USPTO Abstract
Disclosed herein are antisense compounds and methods for decreasing alpha- synuclein mRNA and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.